ASH2022注目テーマ②「Late-Breaking Abstracts Session #2」

PNH経口薬Iptacopanの単剤療法で
ヘモグロビン値が増加、輸血の必要性が減少 Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III APPLY-PNH Study (#LBA-2)

Regis Peffault De Latour（French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France）